Exhibit 99.1
|
CONTACT:
|
|
|
George
J. Longo
|
Carl
Hymans
|
|
Vice
President, CFO
|
G.S.
Schwartz & Co.
|
|
(215)
345-0919
|
(212)
725-4500
|
|
|
carlh@schwartz.com
|
The
Quigley Corporation Names Gerard M. Gleeson To Succeed Retiring George J.
Longo
As Chief
Financial Officer and Director
DOYLESTOWN, PA. –August 6,
2008 – The Quigley Corporation (Nasdaq:
QGLY) today announced that Gerard M. Gleeson has been named to succeed
George J. Longo, who will be retiring from the Company on September 5, 2008, as
Vice President, Chief Financial Officer and as a member of the Board of
Directors. Mr. Gleeson joined The Quigley Corporation in 1998 and has served in
management positions including Corporate Controller of the Company since
2004.
Mr.
Gleeson is a Fellow of the Association of Chartered Certified Accountants, the
global body of professional accountants, with extensive business and industry
acumen that includes tenure as Chief Financial Officer in Ireland for a
subsidiary of Allergan Inc., a multi-national pharmaceutical company.
Additionally, Mr. Gleeson has senior financial management experience in the
retail and service industries.
Guy J.
Quigley, Chairman, President and Chief Executive Officer said, “George Longo has
served as CFO and a Director of the Company since 1997 and played a vital role
in The Quigley Corporation’s successes throughout the years. We are sorry to see
him leave and appreciate all of his contributions to the Company and wish him
well in his retirement.”
About The Quigley
Corporation
The
Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com)
is a diversified natural health medical science company. Its
Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE®
family of lozenges, gums and sugar free tablets clinically proven to cut the
common cold nearly in half. COLD-EEZE customers include leading
national wholesalers and distributors, as well as independent and chain food,
drug and mass merchandise stores and pharmacies. The Quigley
Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists
of two FDA approved facilities to manufacture COLD- EEZE® lozenges as well as
fulfill other contract manufacturing opportunities and Quigley Pharma Inc.
(http://www.QuigleyPharma.com)
conducts research in order to develop and commercialize a pipeline of patented
botanical and naturally derived potential prescription drugs.
Forward-Looking
Statements
Certain
statements in this press release are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and involve
known and unknown risk, uncertainties and other factors that may cause the
Company's actual performance or achievements to be materially different from the
results, performance or achievements expressed or implied by the forward-looking
statement. Factors that impact such forward-looking statements include, among
others, changes in worldwide general economic conditions, changes in interest
rates, government regulations, and worldwide competition.
